Indication
Platinum-Resistant Ovarian Cancer
4 clinical trials
9 products
Clinical trial
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2bStatus: Active (not recruiting), Estimated PCD: 2023-05-31
Product
UpifitamabClinical trial
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2020-07-14
Product
CyclophosphamideProduct
TRX518Product
AvelumabClinical trial
A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)Status: Terminated, Estimated PCD: 2022-11-08
Product
TemozolomideProduct
NTX-301Product
Platinum-based ChemotherapyClinical trial
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-24
Product
Mirvetuximab SoravtansineProduct
Rucaparib